|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS MAY CAUSE SEVERE DROWSINESS & CONFUSION WHEN CONCURRENTLY ADMINISTERED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS INHIBIT SPREADING ACTION
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS AND RENAL SIDE EFFECTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS ; CONCOMITANT TREATMENT MAY BE ASSOCIATED WITH HYPERKALEMIA
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION MAY INTERFERE WITH THE BENEFITS OF ASPIRIN TAKEN FOR HEART DISEASE, SHOULD BE TAKEN ON DIFFERENT TIMES
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT & HYPERKALEMIA
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
DECREASED LITHIUM RENAL CLEARANCE RESULTING IN INCREASED LITHIUM PLASMA LEVELS ; POTENTIAL FOR LITHIUM TOXICITY
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
CO-ADMINISTRATION MAY INCREASE SERUM METHOTREXATE CONCENTRATIONS RESULTING IN METHOTREXATE TOXICITY SINCE NSAIDS MAY AFFECT RENAL PROSTAGLANDINS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
DICLOFENAC CAN INHIBIT THE ACTIVITY OF DIURETICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CNS EXCITATION MAY OCCUR WITH CONCURRENT ADMINISTRATION; MAY CAUSE CONVULSIONS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
BOTH HYPO AND HYPERGLYCEMIC EFFECTS HAVE BEEN REPORTED RARELY ; POSSIBILITY EXISTS THAT DICLOFENAC MAY ALTER PATIENTS RESPONSE TO ORAL HYPOGLYCEMIC AGENTS
|
WHILE STUDIES HAVE NOT SHOWN INTERACTIONS WITH ORAL ANTICOAGULANTS, CONCURRENT THERAPY REQUIRES CLOSE MONITORING OF PATIENTS FOR POTENTIAL MODIFICATION IN ANTICOAGULANTS DOSAGE
|
NSAIDS MAY INCREASE THE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CYCLOSPORINE"S NEPHROTOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION IS NOT RECOMMENDED BECAUSE DICLOFENAC IS DISPLACED FROM ITS BINDING SITE
|
CO-ADMINISTRATION MAY INCREASE SERUM DIGOXIN CONCENTRATION RESULTING IN DIGOXIN TOXICITY SINCE DICLOFENAC MAY AFFECT RENAL PROSTAGLANDINS
|
NSAIDS CONCURRENT ADMINISTRATION SHOULD BE CAUTIOUS AS THESE INHIBIT PROSTAGLANDIN SECRETIONS WHICH MAY REDUCE THE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT OF ACE INHIBITORS
|
CO-ADMINISTRATION OF NSAIDS WITH ACE INHIBITORS MAY RESULT IN DIMINISHED ANTIHYPERTENSIVE EFFECT & HYPERKALEMIA
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|